Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma.

INTERVENTION: Trade Name: Avastin Product Name: Avastin (bevacizumab) Pharmaceutical Form: Injection* CONDITION: Rubeotic glaucoma secondary to ischaemic proliferative retinopathies PRIMARY OUTCOME: Main Objective: To assess the effectiveness of intravitreal bevacizumab in treating rubeotic glaucoma when compared with conventional treatment. ; ; Primary outcomes: ; 1. Iris neovascularisation ; 2. IOP ; 3. IOP medications ; 4. Pain ; 5. Visual acuity ; 6. Need for enucleation; ; Primary end point(s): Primary end points: ; 1. Iris neovascularisation ; 2. IOP ; 3. IOP medications ; 4. Pain ; 5. Visual acuity ; 6. Need for enucleation Secondary Objective: Secondary outcomes: Quality of life, OCT. INCLUSION CRITERIA: Patients with rubeotic glaucoma ( iris or angle neovascularisation and intraocular pressure > 21 mmHg) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range